Lineage Cell Therapeutics vs Surrozen
Lineage Cell Therapeutics is the larger business, with $14.6m of revenue in fiscal 2025 against $3.5m for Surrozen (4.2 times as much). Lineage Cell Therapeutics grew faster (53.2% against -67.4%). Lineage Cell Therapeutics kept more of each dollar of sales as profit: a net margin of -436.5% against -6960.8%.
| Latest fiscal year | Lineage Cell TherapeuticsLCTX, 2025 | SurrozenSRZN, 2025 |
|---|---|---|
| Revenue | $14.6m | $3.5m |
| Revenue growth | 53.2% | -67.4% |
| Net income | −$63.5m | −$242m |
| Operating margin | — | -1210.6% |
| Net margin | -436.5% | -6960.8% |
| Return on equity | -103.4% | — |
| Free cash flow | −$19.4m | −$30.4m |
| Cash | $40.8m | $89.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 77 | 44 |
| Market value | $252m | $351m |
| Price vs our value range | — | — |
| Moat score | 21 (Weak) | — |
| Insider trades, 12 months | 1 buys, 0 sales | 53 buys, 6 sales |